A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study.

@article{Kim2007AND,
  title={A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study.},
  author={Sang Kyoon Kim and Dong Yun Lee and Choong Yong Kim and Jong Hee Nam and Hyun Tae Moon and Youngro Byun},
  journal={Journal of controlled release : official journal of the Controlled Release Society},
  year={2007},
  volume={123 2},
  pages={
          155-63
        }
}
The development of orally active heparin will have tremendous clinical importance since it can be used to effectively prevent deep vein thrombosis (DVT) in a long-term chronic treatment. We developed in this study a new orally active heparin derivative (Db-LHD), which has heparin chemically conjugated with deoxycholic acid and DMSO molecules by secondary interactions. Db-LHD was prepared in the powder form in soft capsules. When we administered Db-LHD capsules to monkeys, its oral physiological… CONTINUE READING
Highly Cited
This paper has 17 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 10 citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats

  • Y. K. Lee, S. K. Kim, +5 authors Y. Byun
  • mice and monkeys, J. Control. Release 111 () 290…
  • 2007
1 Excerpt

Prevention effect of orally active heparin derivative on deep vein thrombosis

  • S. K. Kim, D. Y. Lee, C. Y. Kim, H. T. Moon, Y. Byun
  • Thromb. Haemost. 96
  • 2006
2 Excerpts

Commentary : The rate and extent of oral bioavailability vs . the rate and extent of oral absorption : classification and recommendation of terminology

  • W. B. Paul
  • J . Pharmacokinet . Phar .
  • 2001